Vol 70, No 1 (2019)
Review paper
Published online: 2019-02-22

open access

Page views 6986
Article views/downloads 4591
Get Citation

Connect on Social Media

Connect on Social Media

The content of this article is also available in the following languages:

The effect of biotin interference on the results of blood hormone assays [Wpływ interferencji biotyny na wyniki oznaczeń stężenia hormonów we krwi]

Magdalena Ostrowska1, Zbigniew Bartoszewicz2, Tomasz Bednarczuk2, Klaudia Walczak2, Wojciech Zgliczyński1, Piotr Glinicki1
Pubmed: 30855699
Endokrynol Pol 2019;70(1):102-121.


Approximately 70% of medical decisions are made based on results of laboratory investigations. Immunochemical methods are used most commonly in routine laboratory diagnostics of endocrine disorders. Those methods are limited by susceptibility of the immunochemical reaction to various interferences. Interference may be caused by the presence of autologous antibodies, heterophilic antibodies, or paraproteins in the blood serum, by cross-reactions with similar reagents, haemolysis, significant lipidaemia, or hyperbilirubinaemia. Some recent reports have indicated a significant effect of biotin on the reliability of laboratory investigations. Biotin is a water-soluble vitamin belonging to the B group. It is present in popular dietary supplements — alone or as a component of multi-vitamin formulas — and it is advertised as a remedy to falling out and fragility of hair and nails. Due to its low molecular weight and a strong affinity to streptavidin, biotin is used in many immunochemical tests. Due to a strong and stable bond of streptavidin and biotin, analytical methods using the streptavidin (avidin)–biotin system are characterised by superior sensitivity, and they allow determination of very low levels of the tested substance in biological material. The presence of exogenous biotin in a sample may cause interference when using tests that utilise the streptavidin (avidin)–biotin system. Interference of biotin with immunochemical tests depends on several factors: the construction of the immunochemical test, the dose used by the patient, the biotin concentration in the sample, and most of all — the time from the last dose to the collection of biological material for laboratory testing. In this paper we present some practical recommendations and a procedure to be followed in the case of suspected interference of biotin in immunochemical assays, for clinicians and laboratory diagnosticians.

Article available in PDF format

View PDF Download PDF file


  1. Najwyższa Izba Kontroli. Diagnostyka laboratoryjna w Polsce [panel eskpertów. https://www.nik.gov.pl/aktualnosci/organizacja-i-finansowanie-diagnostyki-laboratoryjnej-panel-ekspertow.html.
  2. Diamandis EP, Christopoulos TK. The biotin-(strept)avidin system: principles and applications in biotechnology. Clin Chem. 1991; 37(5): 625–636.
  3. Mattman A, Potter M. Approach to the interpretation of unexpected laboratory results arising in the care of patients with inborn errors of metabolism (IEM). Rev Endocr Metab Disord. 2018; 19(1): 5–12.
  4. Piketty ML, Polak M, Flechtner I, et al. False biochemical diagnosis of hyperthyroidism in streptavidin-biotin-based immunoassays: the problem of biotin intake and related interferences. Clin Chem Lab Med. 2017; 55(6): 780–788.
  5. Zempleni J, Wijeratne SSK, Hassan YI. Biotin. Biofactors. 2009; 35(1): 36–46.
  6. Batista MC, Ferreira CES, Faulhaber ACL, et al. Biotin interference in immunoassays mimicking subclinical Graves' disease and hyperestrogenism: a case series. Clin Chem Lab Med. 2017; 55(6): e99–e9e103.
  7. Gifford JL, Sadrzadeh S, Naugler C. Biotin interference: Underrecognized patient safety risk in laboratory testing. Can Fam Physician. 2018 ; 64(5): 370.
  8. Piketty ML, Prie D, Sedel F, et al. High-dose biotin therapy leading to false biochemical endocrine profiles: validation of a simple method to overcome biotin interference. Clin Chem Lab Med. 2017; 55(6): 817–825.
  9. Arya VB, Ajzensztejn M, Appleby G, et al. High-dose biotin in infants mimics biochemical hyperthyroidism with some commercial assays. Clin Endocrinol (Oxf). 2018; 88(3): 507–510.
  10. Sedel F, Papeix C, Bellanger A, et al. High doses of biotin in chronic progressive multiple sclerosis: a pilot study. Mult Scler Relat Disord. 2015; 4(2): 159–169.
  11. Li D, Radulescu A, Shrestha RT, et al. Association of Biotin Ingestion With Performance of Hormone and Nonhormone Assays in Healthy Adults. JAMA. 2017; 318(12): 1150–1160.
  12. Samarasinghe S, Meah F, Singh V, et al. Biotin Interference with Routine Clinical Immunoassays: Understand the Causes and Mitigate the Risks. Endocr Pract. 2017; 23(8): 989–998.
  13. Holmes EW, Samarasinghe S, Emanuele MA, et al. Biotin Interference in Clinical Immunoassays: A Cause for Concern. Arch Pathol Lab Med. 2017; 141(11): 1459–1460.
  14. Trambas C, Lu Z, Yen T, et al. Characterization of the scope and magnitude of biotin interference in susceptible Roche Elecsys competitive and sandwich immunoassays. Ann Clin Biochem. 2018; 55(2): 205–215.
  15. Willeman T, Casez O, Faure P, et al. Evaluation of biotin interference on immunoassays: new data for troponin I, digoxin, NT-Pro-BNP, and progesterone. Clin Chem Lab Med. 2017; 55(10): e226–e229.
  16. Meany DL, Beur SMJ, Bill MJ, et al. A case of renal osteodystrophy with unexpected serum intact parathyroid hormone concentrations. Clinical Chemistry. 2009; 55(9): 1737–1739.
  17. Kwok JSS, Chan IHS, Chan MHM. Biotin interference on TSH and free thyroid hormone measurement. Pathology. 2012; 44(3): 278–280.
  18. Wijeratne NG, Doery JCG, Lu ZX. Positive and negative interference in immunoassays following biotin ingestion: a pharmacokinetic study. Pathology. 2012; 44(7): 674–675.
  19. Minkovsky A, Lee MN, Dowlatshahi M, et al. High-dose biotin treatment for secondary progressive multiple sclerosis may interfere with thyroid assays. AACE Clin Case Rep. 2016; 2(4): e370–e373.
  20. Kummer S, Hermsen D, Distelmaier F. Biotin Treatment Mimicking Graves' Disease. N Engl J Med. 2016; 375(7): 704–706.
  21. Henry JG, Sobki S, Arafat N. Interference by biotin therapy on measurement of TSH and FT4 by enzyme immunoassay on Boehringer Mannheim ES700 analyser. Ann Clin Biochem. 1996; 33(Pt 2): 162–163.
  22. Willeman T, Casez O, Faure P. Biotin in multiple sclerosis and false biological hyperthyroidism: Mind the interference. Rev Neurol (Paris). 2017; 173(3): 173–174.
  23. Elston MS, Sehgal S, Du Toit S, et al. Factitious Graves' disease due to biotin immunoassay interference — a case and review of the literature. J Clin Endocrinol Metab. 2016; 101(9): 3251–3255.
  24. Sulaiman RA. Biotin treatment causing erroneous immunoassay results: A word of caution for clinicians. Drug Discov Ther. 2016; 10(6): 338–339.
  25. Evans N, Yates J, Tobin J, et al. Immunoassay interference secondary to therapeutic high-dose biotin: A paediatric case report. J Paediatr Child Health. 2018; 54(5): 572–575.
  26. Waghray A, Milas M, Nyalakonda K, et al. Falsely low parathyroid hormone secondary to biotin interference: a case series. Endocr Pract. 2013; 19(3): 451–455.
  27. US Food and Drug Administration. The FDA warns that biotin may interfere with lab tests: FDA safety communication. https://www.fda.gov/medicaldevices/safety/alertsandnotices/ucm586505.htm.
  28. Koehler VF, Mann U, Nassour A, et al. Fake news? Biotin interference in thyroid immunoassays. Clin Chim Acta. 2018; 484: 320–322.
  29. Cusini C, Sassi L, De Paola G, et al. Apparent biochemical thyrotoxicosis due to assay interference by high-dose biotin given for multiple sclerosis. J Endocrinol Invest. 2017; 40(8): 889–890.
  30. Barbesino G. Misdiagnosis of Graves' disease with apparent severe hyperthyroidism in a patient taking biotin megadoses. Thyroid. 2016; 26(6): 860–863.
  31. Stieglitz HM, Korpi-Steiner N, Katzman B, et al. Suspected Testosterone-Producing Tumor in a Patient Taking Biotin Supplements. J Endocr Soc. 2018; 2(6): 563–569.
  32. Lam L, Bagg W, Smith G, et al. Apparent hyperthyroidism caused by biotin-like interference from IgM anti-atreptavidin antibodies. Thyroid. 2018; 28(8): 1063–1067.
  33. Rulander NJ, Cardamone D, Senior M, et al. Interference from anti-streptavidin antibody. Arch Pathol Lab Med. 2013; 137(8): 1141–1146.
  34. Brugts MP, Luermans JG, Lentjes EG, et al. Heterophilic antibodies may be a cause of falsely low total IGF1 levels. Eur J Endocrinol. 2009; 161(4): 561–565.
  35. Vos MJ, Rondeel JMM, Mijnhout GS, et al. Immunoassay interference caused by heterophilic antibodies interacting with biotin. Clin Chem Lab Med. 2017; 55(6): e122–e126.
  36. Kricka LJ. Human anti-animal antibody interferences in immunological assays. Clin Chem. 1999; 45(7): 942–956.
  37. Heijboer AC, Ijzerman RG, Bouman AA, et al. Two cases of antiruthenium antibody interference in Modular free thyroxine assay. Ann Clin Biochem. 2009; 46(Pt 3): 263–264.
  38. Chen T, Hedman L, Mattila PS, et al. Biotin IgM antibodies in human blood: a previously unknown factor eliciting false results in biotinylation-based immunoassays. PLoS One. 2012; 7(8): e42376.
  39. Lam L, Kyle CV. A simple method to detect biotin interference on immunoassays. Clin Chem Lab Med. 2017; 55(6): e104–e106.
  40. Trambas C, Lu Z, Yen T, et al. Depletion of biotin using streptavidin-coated microparticles: a validated solution to the problem of biotin interference in streptavidin-biotin immunoassays. Ann Clin Biochem. 2018; 55(2): 216–226.